Brixton Biosciences

Brixton Biosciences, a company based in the United States, is developing Neural Ice™, a novel pain management solution intended to provide long-lasting pain relief from a single injection. The company's technology, which was developed at Massachusetts General Hospital, has the potential to address both acute and chronic pain, and is set to undergo its first in-human study in 2023.